FDA Considers Easing Peptide Restrictions, Prompted by RFK Jr.
The Food and Drug Administration (FDA) has announced plans to hold advisory committee meetings on July 23-24, 2026. The purpose of these meetings is to consider the possibility of easing restrictions on seven popular peptide injections. This move comes in response to pressure from Health Secretary Robert F. Kennedy Jr. and signifies a notable shift in the regulation of the wellness industry. These unapproved therapies have seen a surge in popularity among fitness influencers and longevity enthusiasts.
The peptides under review include BPC-157, which is marketed for injury healing and inflammation reduction. Other compounds under consideration are used for wound healing, obesity treatment, and insomnia. Kennedy, a self-proclaimed “big fan of peptides” who claims to have used them for personal injuries, argues that current FDA restrictions have driven consumers to dangerous gray market sources from overseas suppliers.
The FDA plans to remove these peptides from a restrictive list reserved for high-risk drugs, pending the advisory panel’s recommendations. However, critics warn of safety concerns. Former FDA official Dr. Peter Lurie states that the move poses a “profound threat” to the agency’s drug vetting system. The peptides currently lack extensive clinical testing and safety data. Proponents, however, argue that lifting restrictions will bring products “out of the back alley and into the light,” ensuring better quality control through regulated compounding pharmacies.
Source: Stat News